Conferences - Results from #80

ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) June 5, 2022

ASCO 2022: [68Ga]Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to [177Lu]Lu-PSMA-617 in Patients With mCRPC: A VISION Substudy June 5, 2022

ASCO 2022: Metastatic Castration-Resistant Prostate Cancer: The Future Is Now? - Discussion June 5, 2022

ASCO 2022: Preliminary Results of a Phase Ib/II Combination Study of RC48-ADC, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate With Toripalimab, a Humanized IgG4 mAb Against PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma June 5, 2022

ASCO 2022: HER-2 Is New Again in Bladder Cancer - Discussion June 5, 2022

ASCO 2022: Sequencing Challenges in Renal Cell Carcinoma: What to Do Next? - Discussion June 5, 2022

ASCO 2022: Moving Beyond TKI and Immuno-oncology in Renal Cell Carcinoma - Discussion June 5, 2022

ASCO 2022: Reimaging the Timing and Intensity of ADT in Biochemical Recurrence June 5, 2022

ASCO 2022: Improving Outcomes Across the Stages in Bladder Cancer - Discussion June 5, 2022

ASCO 2022: Salvage Treatment for Biochemical Recurrence After Radical Prostatectomy June 5, 2022

ASCO 2022: Pembrolizumab + Axitinib Versus Sunitinib As First-Line Therapy for Advanced Clear Cell RCC: Analysis of Progression After First Subsequent Therapy in KEYNOTE-426 June 5, 2022

ASCO 2022: Molecular-Based Imaging Redefining the Disease Landscape June 4, 2022

ASCO 2022: Long-Term Outcomes in EV-301: 24-Month Findings From the Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma June 4, 2022

ASCO 2022: Perioperative Chemoimmunotherapy With Durvalumab for Operable Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single Arm Phase II Trial SAKK 06/17 June 4, 2022

ASCO 2022: RC48-ADC For Metastatic Urothelial Carcinoma With HER2-Positive: Combined Analysis of RC48-C005 and RC48-C009 Trials June 4, 2022

ASCO 2022: A Phase II Study of RC48-ADC in HER2-Negative Patients With Locally Advanced or Metastatic Urothelial Carcinoma June 4, 2022

ASCO 2022: Avelumab As the Basis of Neoadjuvant Regimen in Platinum-Eligible and -Ineligible Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: AURA (Oncodistinct-004) Trial June 4, 2022

ASCO 2022: Sequential Immunotherapy in Rare Variant Renal Cell Carcinoma Final Report of UNISoN (ANZUP 1602): Nivolumab Then Ipilimumab + Nivolumab in Advanced Nonclear Cell Renal Cell Carcinoma June 4, 2022

ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations June 4, 2022

ASCO 2022: Outcomes With Novel Combinations in Non-Clear Cell RCC: ORACLE Study June 4, 2022

Page 5 of 472

email news signup